Regeneron Pharmaceuticals Financials - Benzinga

Regeneron Pharmaceuticals Inc

REGNNASDAQ

Trade with Public

Trade with Public

$796.02

-5.80-0.72%

al cierre: Sep 24, 5:00 PM EST

$796.02

-5.80-0.72%

After hour: 4:00 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Dividendos Comparar Opciones Informe de acciones

Regeneron Pharmaceuticals Financials

Regeneron Pharmaceuticals (REGN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Regeneron Pharmaceuticals Q2 Adj. EPS $14.29 Beats $10.26 Estimate, Sales $4.291B Beat $3.816B Estimate

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $14.29 per share which beat the analyst consensus estimate of $10.26 by 39.28 percent. This is a 10.86 percent increase over earnings of $12.89 per

Benzinga Newsdesk

Stock Market Today: Dow, S&P 500, Nasdaq Futures Drop After UAE Nuclear Plant Strike— Regeneron Pharma, NextNRG, ServiceNow In Focus (UPDATED)

Editor’s note: The future prices of benchmark tracking ETFs, and the headline were updated in the story.

Rishabh Mishra

Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings

Regeneron Pharmaceuticals (NASDAQ: REGN) reported strong Q1 earnings and a $3B share buyback. Analysts have mixed views on the stock.

Avi Kapoor

Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe

Regeneron beats Q1 estimates as Eylea HD demand rises, while margins narrow and FDA decisions on manufacturing remain pending.

Vandana Singh

Earnings Scheduled For April 29, 2026

Benzinga Insights

PRO
Regeneron Pharmaceuticals Q1 Adj. EPS $9.47 Beats $8.89 Estimate, Sales $3.605B Beat $3.483B Estimate

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $9.47 per share which beat the analyst consensus estimate of $8.89 by 6.52 percent. This is a 15.21 percent increase over earnings of $8.22 per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved